Filter Results:
(481)
Show Results For
- All HBS Web (481)
- Faculty Publications (364)
Show Results For
- All HBS Web (481)
- Faculty Publications (364)
- October 1988 (Revised November 1988)
- Case
Du Pont: Biotechnology in Agricultural Products
By: Ray A. Goldberg
Goldberg, Ray A. "Du Pont: Biotechnology in Agricultural Products." Harvard Business School Case 589-058, October 1988. (Revised November 1988.)
- November 1991
- Case
Monsanto's March into Biotechnology (B) (Abridged)
By: Dorothy Leonard-Barton and Alistair D. Williamson
Keywords: Biotechnology Industry
Leonard-Barton, Dorothy, and Alistair D. Williamson. "Monsanto's March into Biotechnology (B) (Abridged)." Harvard Business School Case 692-067, November 1991.
- March 1992 (Revised June 2005)
- Teaching Note
Monsanto's March into Biotechnology (A), Teaching Note
By: Dorothy Leonard-Barton and Alistair D. Williamson
Teaching Note for (9-690-009). View Details
Keywords: Biotechnology Industry
- January 2000
- Article
The Tragedy of the Commoners: Biotechnology and its Publics
By: Arthur A. Daemmrich
Keywords: Biotechnology Industry
Daemmrich, Arthur A. "The Tragedy of the Commoners: Biotechnology and its Publics." Nature Biotechnology 18, no. 1 (January 2000): 2–4.
- March 2011
- Case
MorphoSys AG: The Evolution of a Biotechnology Business Model
By: Gary P. Pisano, Ryan Johnson and Carin-Isabel Knoop
In the biotech world, the 18-year-old Munich-based company MorphoSys was a rarity: it was profitable. The company achieved this profitability not by developing and selling its own drugs, but by licensing access to its proprietary library of human antibodies. Recently,... View Details
Keywords: Business Model; Profit; Intellectual Property; Rights; Risk Management; Digital Platforms; Product Development; Business and Shareholder Relations; Vertical Integration; Biotechnology Industry; Munich
Pisano, Gary P., Ryan Johnson, and Carin-Isabel Knoop. "MorphoSys AG: The Evolution of a Biotechnology Business Model." Harvard Business School Case 611-046, March 2011.
- Article
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By: Josh Lerner, Hilary Shane and Alexander Tsai
Lerner, Josh, Hilary Shane, and Alexander Tsai. "Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances." Journal of Financial Economics 67, no. 3 (March 2003): 411–446. (Earlier versions distributed as HBS Working Paper No. 00-038 and NBER Working Paper No. 7464.)
- February 2012
- Article
A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational
By: Prithwiraj Choudhury, James Geraghty and Tarun Khanna
We build on the emerging literature of influence-based models to study how multinational firms can navigate host governments. Our "core-periphery" framework posits that the actions that an MNC takes with actors in what we call the "periphery"—comprised of state,... View Details
Keywords: Emerging Markets; Multinational Firms and Management; Business and Government Relations; Power and Influence; Framework; Biotechnology Industry; Massachusetts; Brazil; China; Costa Rica; France; India
Choudhury, Prithwiraj, James Geraghty, and Tarun Khanna. "A 'Core Periphery' Framework to Navigate Emerging Market Governments—Qualitative Evidence from a Biotechnology Multinational." Global Strategy Journal 2, no. 1 (February 2012): 71–87.
- February 1986 (Revised November 1992)
- Case
Novo Industri A/S--1981
By: W. Carl Kester and Glynn Ferguson
This small but rapidly growing Danish biochemical company must choose among several financing opportunities that include a convertible Eurobond, a rights offering in Denmark and an issue of new common shares in the United States. The case involves a broad range of... View Details
Keywords: Capital Markets; Cost of Capital; Bonds; Stock Shares; Financing and Loans; Globalization; Biotechnology Industry; Biotechnology Industry; Denmark; United States
Kester, W. Carl, and Glynn Ferguson. "Novo Industri A/S--1981." Harvard Business School Case 286-084, February 1986. (Revised November 1992.)
- July 2013
- Case
Sample6: Innovating to Make Food Safer
By: Robert F. Higgins and Kirsten Kester
Tim Curran, CEO of Sample6, a start-up biotechnology company developing a novel food safety diagnostics platform, must decide how to partner with food industry players. How can he best convince leaders in this mature industry to adopt a new technology and improve food... View Details
Keywords: Data Analytics; Food Safety; Biotechnology; Nutrition; Entrepreneurship; Product; Partners and Partnerships; Food; Technological Innovation; Business Startups; Governing Rules, Regulations, and Reforms; Product Development; Agribusiness; Information Technology; Globalization; Performance Improvement; Safety; Technology Adoption; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; United States; Boston; Massachusetts
Higgins, Robert F., and Kirsten Kester. "Sample6: Innovating to Make Food Safer." Harvard Business School Case 814-014, July 2013.
- October 2016 (Revised February 2017)
- Teaching Note
Alvogen
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details
- February 2003
- Article
The Geography of Opportunity: Spatial Heterogeneity in Founding Rates and the Performance of Biotechnology Rirms
Stuart, Toby E., and Olav Sorenson. "The Geography of Opportunity: Spatial Heterogeneity in Founding Rates and the Performance of Biotechnology Rirms." Research Policy 32, no. 2 (February 2003): 229–253.
- Article
Discontinuities and Senior Management: Assessing the Role of Recognition in Pharmaceutical Firm Response to Biotechnology
By: Rebecca M. Henderson, Sarah Kaplan and Fiona Murray
Henderson, Rebecca M., Sarah Kaplan, and Fiona Murray. "Discontinuities and Senior Management: Assessing the Role of Recognition in Pharmaceutical Firm Response to Biotechnology." Industrial and Corporate Change 12, no. 2 (April 2003).
- Web
Industry Information - Alumni
recruitment and job seeking opportunities for professionals in the biotechnology and pharmaceutical industries. + – Hospitality Hospitality - General SmartBriefs – Travel Newsletter digest of hospitality View Details
- December 2006 (Revised January 2008)
- Case
ViaGen: Revolutionizing the Livestock Industry
By: David E. Bell, Reed Martin and Mary L. Shelman
ViaGen has invested heavily to develop cloning technology for the livestock industry. Cloning has the potential to significantly improve the genetics of livestock, leading to higher quality meat, healthier animals, and more efficient production. Since 2003, the firm... View Details
Keywords: Animal-Based Agribusiness; Business Plan; Governing Rules, Regulations, and Reforms; Marketing Communications; Industry Structures; Business and Government Relations; Genetics; Commercialization; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry
Bell, David E., Reed Martin, and Mary L. Shelman. "ViaGen: Revolutionizing the Livestock Industry." Harvard Business School Case 507-021, December 2006. (Revised January 2008.)
- Research Summary
Industrial competitiveness in high tech and science-based businesses
By: Willy C. Shih
How do emerging economies develop industrial and technical capabilities that overtake those of advanced economies? Are there some industrial sectors that are especially susceptible to such targeting? What will it take to restore America’s... View Details
- June 1990 (Revised April 1993)
- Teaching Note
Novo Industri A/S--1981, Teaching Note
By: W. Carl Kester
Teaching Note for (9-286-084). View Details
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
Mixing Risk And Reward The basic model that the biotechnology industry has followed for over twenty years is also changing, and for the better, according to panelists at a session titled "Will Equal... View Details
- April 2014
- Case
Merrimack Pharmaceuticals, Inc. (A)
By: Amy C. Edmondson, Bethany S. Gerstein and Melissa Valentine
In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition to interdisciplinary teams. As a small company, Merrimack's R&D organization had... View Details
Keywords: Teamwork; Interdisciplinary Collaboration; R＆D; Biotechnology; Complexity; Innovation Management; Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Biotechnology Industry; Biotechnology Industry
Edmondson, Amy C., Bethany S. Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (A)." Harvard Business School Case 614-063, April 2014.
- October 2011
- Case
Gene Sequencing: Staking a Position in an Expanding Industry
By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews
Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would... View Details
Keywords: Genetics; Business Growth and Maturation; Business Plan; Competition; Venture Capital; Biotechnology Industry
Hamermesh, Richard G., Mara Aspinall, and Phillip Andrews. "Gene Sequencing: Staking a Position in an Expanding Industry." Harvard Business School Case 812-004, October 2011.